SEHK:1801Biotechs
Is Mazdutide’s Phase 3 Success Reshaping the Investment Case for Innovent Biologics (SEHK:1801)?
Innovent Biologics announced that its Phase 3 GLORY-2 clinical trial of mazdutide, a dual GCG/GLP-1 receptor agonist, in Chinese adults with obesity met all primary and secondary endpoints, and the company intends to submit a new drug application in China for weight management use.
This marks mazdutide as the first innovative endocrinology and metabolic drug in China with clinical results published in The New England Journal of Medicine, highlighting its international scientific...